Introducing a non-invasive blood test for advanced liver fibrosis due to NASH
As many as 4 to 6 million people are projected to have advanced fibrosis due to NASH1
By 2030, NASH (non-alcoholic steatohepatitis) is predicted to be the #1 leading indication for liver transplant.1,2 Our Enhanced Liver Fibrosis (ELF™) Test is the first blood test granted De Novo marketing authorization by the FDA for prognosis in advanced fibrosis due to NASH.
Want to know more about our innovations? Join us for the AACC 2021 Virtual Experience.
Vond u deze informatie nuttig?
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
1
Estes C, Razavi H, Loomba, R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-3
2
Younossi ZM, et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes Hepatology. 2016;64(1): 73-84